PBAC's latest decision on Ursodeoxycholic acid: Recommended (2023). Considered for Treatment of primary biliary cholangitis (previously known as primary biliary cirrhosis). This is a request to increase the maximum number of repeats from 2 to 4 for existing PBS listings.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2017
Submissions
2
2017 → 2023
Eligible population
Patients with primary biliary cholangitis requiring chronic long-term treatment with ursodeoxycholic acid.
Therapy area
Hepatology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
Cost-minimisation
ICER note
No economic analysis was submitted. Category 4 submission (administrative change to repeats only).
Submission history
Mar 2017: Recommended with restriction · Authority Required